Filing Details

Accession Number:
0001209191-14-003192
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-14 20:00:24
Reporting Period:
2014-01-10
Filing Date:
2014-01-14
Accepted Time:
2014-01-14 20:00:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001233 Sangamo Biosciences Inc SGMO Biological Products, (No Disgnostic Substances) (2836) 680359556
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1302390 Ward Henry Wolff C/O Sangamo Biosciences Inc.
Point Richmond Tech Cntr, 501 Canal Blvd
Richmond CA 94804
Exec Vp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-01-10 10,000 $3.45 237,347 No 4 M Direct
Common Stock Disposition 2014-01-10 10,000 $18.69 227,347 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Acquisiton 2014-01-10 10,000 $0.00 10,000 $3.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
202,000 2018-12-29 No 4 M Direct
Footnotes
  1. Includes 50,000 shares, 30,000 shares, and 35,000 shares subject to RSUs granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.
  2. All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.38 to $19.31, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. All shares underlying these options are vested and exercisable immediately.